R&D channel feed – Endpoints News

R&D channel feed

Manufacturing roundup: Symeres buys CRO in New Jersey; Cambrex invests $16M+ in Minnesota and Iowa facilities

3 years ago

Broad and MIT scientists repurpose hot RNA editing tech as ‘radar’ with uses in cancer and brain research

3 years ago

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

3 years ago

Plant-based Covid-19 vaccine developer Medicago laying off 60+ at North Carolina plant

3 years ago

AstraZeneca's Ultomiris reduces episode occurrence in NMOSD, meeting primary and secondary endpoints

3 years ago

Takeda bumps Entyvio peak sales, lays out dengue vaccine plans and celiac pipeline in latest earnings call

3 years ago

Moderna nearing deal with US government to develop Ebola vaccines — report

3 years ago

‘Unlikely to transform patient care’: GSK punts top late-stage drug after PhIII data disappoint

3 years ago

Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge

3 years ago

Having cemented its name in long-read sequencing, PacBio takes a stab at Illumina with new short-read tech

3 years ago

Vaxcyte's data lead to $600M haul, while Taysha looks to raise cash after Astellas deal

3 years ago

FDA sets Seres on the priority review path for its microbiome C. difficile drug, setting up April decision

3 years ago

AstraZeneca spotlights positive PhII, PhIII readout for a pair of next-gen breast cancer drugs

3 years ago

AstraZeneca's blockbuster Fasenra fails on one of two PhIII eosinophilic esophagitis trial endpoints

3 years ago

Novartis tosses more US PD-1 submission plans and another anti-CD40 drug indication

3 years ago

Recursion discreetly culls a rare disease program to focus on cancer, pulls in $150M private placement

3 years ago

In bid to keep itself afloat, tiny Diffusion Pharmaceuticals mulls out-licensing core tech or company sale

3 years ago

Gritstone bio secures PIPE financing as it unveils PhI data for vaccine candidate

3 years ago

Alto Neuroscience continues march toward the clinic with Series B, hoping to unveil data next year

3 years ago

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

3 years ago

J&J uncorks new Tremfya data in ulcerative colitis as its rival awaits an FDA decision

3 years ago

Tricida bet its future on one last readout for its CKD drug. Now that’s all but gone

3 years ago

After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win

3 years ago

The namesake behind Harvard’s Wyss Institute has made his fourth donation, this time to the tune of $350M

3 years ago

First page Previous page 113 114 115116117 118 119 Next page Last page